Administrative Core A

行政核心A

基本信息

  • 批准号:
    10891051
  • 负责人:
  • 金额:
    $ 24.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-03-15 至 2025-01-31
  • 项目状态:
    未结题

项目摘要

CORE A: Abstract/Summary Core A provides leadership, management, organizational structure, fiscal oversight, and scientific direction to the Penn Mental Health AIDS Research Center (PMHARC), enabling it to fulfill its core mission to transform how people with both mental illness and HIV are treated and managed, an explicit focus not currently pursued by any other NIMH AIDS Research Center (ARC). PMHARC is unique in: 1) its scientific focus on mental health issues in HIV through an integration of basic, biological and social and behavioral sciences; 2) its unique behavioral and specimen repository and status as the only Behavioral ARC with a Laboratory and Biobehavioral Markers Core; 3) its development of a successful co-funding model with CFAR for PMHARC pilots; and 4) its status as the only NIMH Behavioral ARC collaborating with the NIMH Neuro ARCs in the NIMH Joint Seminar Series. The Center and Core A is led by a Director and two Co-Directors with exceptional and complementary strengths and experience in administration, research, and training and in the study of comorbid mental illness/HIV. PMHARC is located in an optimal intellectual and resource environment, which encompasses robust and well-regarded mental health and HIV research communities on the Penn/CHOP/Wistar contiguous campuses. Through Core A, PMHARC will continue to optimize psychiatric, behavioral, and medical outcomes for those with comorbid mental illness/HIV and elucidate the biological, psychological, and behavioral mechanisms underlying these combined illnesses and treatments. Core A has created an interactive environment that fosters communication, collaboration, and synergy among Center components and participants, as well as with the relevant schools, departments, centers, and institutes at Penn/CHOP/Wistar including CFAR, CTSA, Delaney Collaboratories at Wistar and Temple, and other ARCs. Core A will be engaged and responsible for: 1) coordinating interdisciplinary and collaborative mental health/HIV research; 2) encouraging, supporting, and mentoring new, established, and transitional investigators to focus on comorbid mental illness/HIV, and related comorbidities; 3) developing vibrant and responsive Strategic Planning, Monitoring, and Evaluation Processes and comprehensive Policies and Procedures; 4) managing fiscal matters; 5) conducting educational and community outreach programs; 6) fostering national linkages among other ARCs; and 7) supporting an active Community Advisory Board (CAB). Core A also includes 3 Consultants, Executive Committee (EC), Internal Advisory Board (IAB), External Advisory Committee (EAC), Research Innovation and Diversity Committee (RIDC), and CAB. This structure is explicitly intended to allow for continuous monitoring and evaluation in order to optimize efficiencies and responsiveness. In its first two cycles, PMHARC has made impressive progress in: advancing Diversity/ Inclusion; engaging investigators in combined HIV/mental health research and promoting research infrastructure; identifying, mentoring, and promoting career advancement of Early Stage Investigators (ESIs); and producing an impressive return on investment of the pilot award program.
核心A:摘要/摘要 核心A提供领导、管理、组织结构、财务监督和科学指导,以 宾夕法尼亚大学心理健康艾滋病研究中心(PMHARC),使其能够履行其核心使命,改变 同时患有精神疾病和艾滋病毒的人得到治疗和管理,这是目前没有任何人追求的明确重点 其他国家艾滋病研究中心(ARC)。PMHARC的独特之处在于:1)它对心理健康问题的科学关注 通过整合基础、生物、社会和行为科学研究艾滋病毒;2)其独特的行为 和标本库以及作为唯一拥有实验室和生物行为标记物的行为ARC的地位 CORE;3)为PMHARC飞行员制定了与CFAR成功的联合筹资模式;4)其地位为 在NIMH联合研讨会系列中,唯一与NIMH神经弧合作的NIMH行为ARC。这个 中心和核心A由一名董事和两名联席董事领导,他们具有特殊和互补的优势和 有管理、研究和培训以及研究精神疾病/艾滋病毒共病的经验。PMHARC 位于最佳的智力和资源环境中,其中包括强大的和良好的 心理健康和艾滋病毒研究社区在宾夕法尼亚大学/CHOP/Wistar毗邻的校园。直通核心 A,PMHARC将继续优化并存患者的精神、行为和医学结果 精神疾病/艾滋病毒,并阐明其背后的生物学、心理和行为机制 疾病与治疗相结合。核心A创造了一个促进沟通的互动环境, 中心各组成部分和参与者之间以及与相关学校之间的协作和协同作用, 宾夕法尼亚大学/CHOP/Wistar的部门、中心和研究所,包括CFAR、CTSA、Delaney协作室 威斯塔尔和坦普尔,以及其他弧线。核心A将参与并负责:1)协调跨学科 和协作精神健康/艾滋病毒研究;2)鼓励、支持和指导新的、已建立的和 过渡期调查人员,重点关注精神疾病/艾滋病毒及其相关并存问题;3)发展 充满活力和反应迅速的战略规划、监测和评估进程以及综合政策 和程序;4)管理财政事务;5)开展教育和社区外展计划;6) 促进其他区域间的国家联系;7)支持积极的社区咨询委员会(CAB)。 核心A还包括3名顾问、执行委员会(EC)、内部咨询委员会(IAB)、外部咨询 委员会(EAC)、研究创新和多样性委员会(RIDC)和CAB。这种结构是明确的 旨在进行持续监测和评价,以优化效率和反应能力。 在头两个周期中,PMHARC在以下方面取得了令人印象深刻的进展:促进多样性/包容性;参与 艾滋病毒/精神卫生综合研究和促进研究基础设施的调查人员;确定, 指导和促进早期调查人员的职业发展(ESIS);并制作一份令人印象深刻的 试点奖励计划的投资回报。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID S METZGER其他文献

DAVID S METZGER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID S METZGER', 18)}}的其他基金

Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment
mu-阿片受体结合对 HIV 感染者、ART 抑制的阿片类药物使用障碍患者微生物易位和残余免疫激活的影响,开始药物辅助治疗
  • 批准号:
    10197865
  • 财政年份:
    2019
  • 资助金额:
    $ 24.38万
  • 项目类别:
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment
mu-阿片受体结合对 HIV 感染者、ART 抑制的阿片类药物使用障碍患者微生物易位和残余免疫激活的影响,开始药物辅助治疗
  • 批准号:
    10436808
  • 财政年份:
    2019
  • 资助金额:
    $ 24.38万
  • 项目类别:
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment
mu-阿片受体结合对 HIV 感染者、ART 抑制的阿片类药物使用障碍患者微生物易位和残余免疫激活的影响,开始药物辅助治疗
  • 批准号:
    10654008
  • 财政年份:
    2019
  • 资助金额:
    $ 24.38万
  • 项目类别:
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment
mu-阿片受体结合对 HIV 感染者、ART 抑制的阿片类药物使用障碍患者微生物易位和残余免疫激活的影响,开始药物辅助治疗
  • 批准号:
    10004224
  • 财政年份:
    2019
  • 资助金额:
    $ 24.38万
  • 项目类别:
Rapid initiation of buprenorphine/naloxone to optimize MAT utilization in Philadelphia
快速启动丁丙诺啡/纳洛酮以优化费城 MAT 的利用
  • 批准号:
    9896726
  • 财政年份:
    2018
  • 资助金额:
    $ 24.38万
  • 项目类别:
Core B: Developmental core
核心B:发展核心
  • 批准号:
    10090663
  • 财政年份:
    2013
  • 资助金额:
    $ 24.38万
  • 项目类别:
Efficacy of Drug-HIV counseling among IDU at Methadone clinics in Jakarta
雅加达美沙酮诊所注射吸毒者药物艾滋病毒咨询的效果
  • 批准号:
    7835556
  • 财政年份:
    2009
  • 资助金额:
    $ 24.38万
  • 项目类别:
Efficacy of Drug-HIV counseling among IDU at Methadone clinics in Jakarta
雅加达美沙酮诊所注射吸毒者药物艾滋病毒咨询的效果
  • 批准号:
    8261981
  • 财政年份:
    2009
  • 资助金额:
    $ 24.38万
  • 项目类别:
Efficacy of Drug-HIV counseling among IDU at Methadone clinics in Jakarta
雅加达美沙酮诊所注射吸毒者药物艾滋病毒咨询的效果
  • 批准号:
    7687184
  • 财政年份:
    2009
  • 资助金额:
    $ 24.38万
  • 项目类别:
Efficacy of Drug-HIV counseling among IDU at Methadone clinics in Jakarta
雅加达美沙酮诊所注射吸毒者药物艾滋病毒咨询的效果
  • 批准号:
    8085908
  • 财政年份:
    2009
  • 资助金额:
    $ 24.38万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 24.38万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.38万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 24.38万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.38万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 24.38万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 24.38万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.38万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 24.38万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 24.38万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.38万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了